(NaturalNews) The FDA has started an investigation into whether the diet drug orlistat, marketed as both Alli and Xenical, has been causing serious liver damage in some patients.
Prescription-strength Xenical was approved by the FDA in 1999. Half-strength Alli was approved as the first (and to date, only) over-the-counter weight loss drug in 2007.
Since 1999, there have been 32 adverse event reports linking orlistat to severe liver damage. Twenty-seven patients have been hospitalized for liver problems, and six suffered from outright liver failure. Both of the cases involving Alli took place within the United States, while the other 30 cases, involving Xenical, all took place in other countries.
The FDA discussed its concerns with orlistat at an April meeting of the agency's Center for Drug Evaluation and Research Drug Safety Oversight Board, then eventually decided to further investigate the issue. It is also reviewing data on other potential cases of liver damage submitted by GlaxoSmithKline, which markets Alli, and Roche, which markets Xenical.
"The issues here are complex, but the FDA has benefited from the input of the Board, including comments from representatives from three FDA Centers and several other agencies in the Department of Health and Human Services," said Steven Osborne, executive director of the Drug Safety Oversight Board.
Orlistat has been a big hit for both Glaxo and Roche, which reported $123 million and $472 million in sales of the drug last year, respectively. A Glaxo representative denied that the drug was responsible for the cases of liver damage, noting that the overweight are already at risk for liver disorders.
But the FDA has cautioned that all people taking Alli
or Xenical contact their doctors immediately if they suffer any symptoms of liver damage, including fatigue, fever, nausea, vomiting, jaundice, brown urine or stomach pain. Loss of appetite, itchiness and light-colored stools may be signs of more advanced liver damage
Sources for this story include: www.dailymail.co.uk;
Have comments on this article? Post them here:
people have commented on this article.